Characterization of niphatenones that inhibit androgen receptor N-terminal domain.
Androgen ablation therapy causes a temporary reduction in tumor burden in patients with advanced prostate cancer. Unfortunately the malignancy will return to form lethal castration-recurrent prostate cancer (CRPC). The androgen receptor (AR) remains transcriptionally active in CRPC in spite of castr...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Public Library of Science (PLoS)
2014-01-01
|
| Ráidu: | PLoS ONE |
| Liŋkkat: | http://europepmc.org/articles/PMC4182434?pdf=render |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
